Hybridoma Technology: Lab made Antibodies!
Introduction Hybridoma technology is a method for producing large quantities of monoclonal antibodies (MAbs) by fusing a specific type of white blood cell (B-cell) with a myeloma (cancer) cell. This technology allows for the production of antibodies that are identical (monoclonal), providing high specificity and consistency in binding to the target antigen. Historical Background The technique was first developed by Georges Köhler and César Milstein in 1975, for which they were awarded the Nobel Prize in 1984. Hybridoma technology revolutionized immunology, leading to significant advances in diagnostic and therapeutic applications. Procedure Fig 1: General Procdure Immunization of Host Animal: Objective: The goal is to induce a robust immune response in the host animal (commonly a mouse), leading to the production of B-cells that generate antibodies specific to the antigen of...